Achiko reports an EBITDA loss of USD 4.6 million, including a non-cash share compensation expense of USD 1 million, incurred whilst transforming the company and moving to commercialisation.Focal points of the first half year were completion of product registration, organisational reconfiguration and … [Read more...]
Achiko AG: Invitation to the H1 2021 Financial Results Presentation
Zurich, 23 September 2021Achiko AG (SWX: ACHI, ISIN CH0522213468), a global healthtech company currently developing technologies that seek to deliver rapid, affordable diagnostic testing for Covid-19 and a range of other pathogenic diseases and therapeutic indications, will hold a H1 2021 … [Read more...]
Achiko’s rapid Covid-19 diagnostic test AptameX™ receives product and registration approval from Indonesia’s Ministry of Health
AptameXTM, Achiko’s breakthrough DNA aptamer-based diagnostic test for Covid-19, received product and registration emergency use approval from the Ministry of Health in Indonesia, alongside its sister digital passporting service, Teman SehatTM (“Health Buddy”).PT Achiko Medika Indonesia, which is … [Read more...]
Achiko engages EpiMetrics to expand Covid-19 testing operations with Udayana University in Bali, Indonesia in the implementation of a mass testing program
Zurich, 15 July 2021: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”), a global healthtech company currently developing technologies that seek to deliver rapid, affordable diagnostic testing for Covid-19 and a range of other … [Read more...]
Achiko announces an extension of its Convertible Loan Transaction with Negma Group
Zurich, 18 June 2021 – Achiko AG (SWX:ACHI, ISIN CH0522213468) (“Achiko”, the “Company”) has successfully extended the subordinated convertible loan agreement of CHF 900,000 dated 8 March 2021 to CHF 1,650,000 thereby granting Achiko an additional CHF 750,000 to be used on product development, sales … [Read more...]